Furthermore, the combination of the GNP-LO91-99 nanovaccine and anti-PD-1 or anti-CTLA-4 antibodies can reduce immune checkpoint expression and increase tumour sensitivity to the vaccine. The gene discussed is PDCD1; the disease is neoplasm.